Reuters logo
BRIEF-Abbvie's investigational HCV regimen receives FDA Breakthrough Therapy Designation
September 30, 2016 / 12:21 PM / a year ago

BRIEF-Abbvie's investigational HCV regimen receives FDA Breakthrough Therapy Designation

Sept 30 (Reuters) - Abbvie Inc :

* AbbVie’s investigational HCV regimen receives U.S. FDA Breakthrough Therapy Designation Source text for Eikon: Further company coverage: ;))

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below